CD86+or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis

Blood

Volumn 120, Issue 10, 2012, Pages 2055-2063

  Brown, Ross ^a   Kabani, Karieshma ^a   Favaloro, James ^a   Yang, Shihong ^a   Ho, P Joy ^a   Gibson, John ^a   Fromm, Phillip ^b   Suen, Hayley ^a   Woodland, Narelle ^c   Nassif, Najah ^c   Hart, Derek ^b   Joshua, Douglas ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ANZAC RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA G ANTIGEN;

ARTICLE; BLOOD; BONE MARROW; CANCER CELL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; MYELOMA CELL; NATURAL KILLER CELL; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84866156002     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-416792     Document Type: Article

References (40)

1. Joly E, Hudriser D. What is trogocytosis and what is its purpose? Nat Immunol. 2003;4(9):815.
2. Huang J-F, Yang Y, Sepulveda H, et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science. 1999;286(5441):952-954.
3. Hudrisier D, Bogrand P. Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance. FASEB J. 2002;16(6):477-486.
4. Wetzel S, Parker D. MHC transfer from APC to T cells following antigen recognition. Crit Rev Immunol. 2006;26(1):1-21.
5. Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol. 2007;7(3):238-243.
6. Riond J, Elhmouzi J, Hudriser D, Gairin JE. Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter with CD8(+) cells. Scand J Immunol. 2007;66(4):441-450.
7. Ahmed KA, Munegowda M, Xie Y, Xiang J. Intercellular trogocytosis plays an important role in modulation of immune responses. Cell Mol Immunol. 2008;5(4):261-269.
8. LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007;109(5):2040-2048.
9. Wiendl H. Fast track to becoming a regulatory T cell: "trogocytosis" of immune-tolerogenic HLA-G. Blood. 2007;109(5):1796-1797.
10. Tárnok A. Patch bandits. Cytometry. 2009;75(5):377-379.
11. Sabzevari H, Kantor J, Jaigirdar A, et al. Acquisition of CD80 (B7-1) by T cells. J Immunol. 2001;166(4):2505-2513.
12. Vahlenkamp TW, Bull ME, Dow JL, et al. B7+CTLA4+ T cells engage in T-T cell interactions that mediate apoptosis: a model for lentivirus-induced T cell depletion. Vet Immunol Immunopathol. 2004;98(304):203-214.
13. Machlenkin A, Uzana R, Frankenberg S, et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Res. 2008;68(6):2006-2013.
14. Behrens L, Kerschensteiner M, Misgeld T, Goebels N et al. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol. 1998; 161(11):5943-5951.
15. Liu W, Putman AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. Exp Med. 2006;203(7):1701-1711.
16. Daubeuf S, Lindorfer MA, Taylor RP, Hudrisier D. The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J Immunol. 2010;184(4):1897- 1908.
17. Venken K, Thewissen M, Hellings N, et al. A CFSE based assay for measuring CD4+ CD25+ regulatory T cell mediated suppression of autoantogen specific and polyclonal T-cell responses. J Immunol. 2007;322(1-2):1-11.
18. Rouas-Freiss N, Gonçalves RM-B, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. PNAS. 1997;94(21):11520-11525.
19. Riteau B, Menier C, Khalil-Daher I, et al. HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol. 1999;43;(2):203-211.
20. Gros F, Cabillic F, Toutirais O, et al. Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur J Immunol. 2008;38(3):742-749.
21. Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoposis in activated CD8 cells by interacting with CD8. J Immunol. 2000; 164(12):6100-6104.
22. Naji A, Rond SL, Durrbach A, et al. CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood. 2007;110(12):3936-3948.
23. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, LeMaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 2008;111(10):4862-4870.
24. Feger U, Tolosa E, Huang Y-H, et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood. 2007;110(2):568-577.
25. Maki G, Hayes G, Naji A, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22(5):998-1006.
26. Nückel H, Rebmann V, Durig J, et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105(4):1694-1698.
27. Sebti Y, Maux AL, Gros F, et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Brit J Haematol. 2007;138(2):202-212.
28. Poláková K, Ová MK, Kuba D, Russ G. Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res. 2003; 27(7):643-648.
29. Amiot L, Onno M, Renard I, et al. HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens. 1996;48(5):609-614.
30. Urosevic M, Kamarashev J, Burg G, Dummer R. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Blood. 2005;103(5):1796-1798.
31. Yan W-H, Lin A, Chen B-G, et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukemia. J Cell Mol Med. 2008;12(3):889-898.
32. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12:133-143.
33. Loh YSC, Mo S, Brown RD, et al. Presence of hoechst low side populations in multiple myeloma. Leuk Lymph. 2008;49:1813-1816.
34. Tamura H, Dan K, Tamada K, et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res. 2005;11(16):5708-5717.
35. Shah R, Banks K, Patel A, et al. Intense expression of the B7.2 antigen presentation coactivator is an unfavorable prognostic indicator for differentiated thyroid carcinoma of children and adolescents. J Clin Endocrinol Metab. 2002;87(9):4391-4397.
36. Pope B, Brown RD, Gibson J, Yuen E, Joshua D. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood. 2000;96(4):1274-1279.
37. Perez-Andres M, Almelda J, Martin-Ayuso M, et al. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer. 2009;124(2):367-375.
38. Mostböck S, Catalfamo M, Tagaya Y, et al. Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory homeostasis. Blood. 2007;109(6):2488-2495.
39. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
40. Bogen B. A mouse model for immunotherapy of myeloma. Hematol J. 2002;3(5):224-229.